Literature DB >> 7082852

Agonist action of yohimbine on the perfused rabbit central ear artery.

F M Tayo.   

Abstract

The agonist action of yohimbine, an alpha-adrenoceptor antagonist, was studied on the perfused ear artery of the rabbit. Yohimbine, 5-hydroxytryptamine (5-HT) and noradrenaline produced concentration-dependent vasoconstriction of the central ear artery and gave EC50 values of 3.5 X 10(-7), 7.5 X 10(-9) and 3.0 X 10(-10) M, respectively. Phentolamine significantly reduced the effects of yohimbine, 5-HT and noradrenaline, and gave pA2 values of 8.40 (slope = 1.0), 8.60 (slope = 0.94) and 8.20 (slope = 1.04), respectively. Methysergide, a serotonergic antagonist, significantly reduced yohimbine- and 5-HT-induced vasoconstriction but failed to influence the effect of noradrenaline. Reserpine treatment induced hypersensitivity of the ear artery to yohimbine and noradrenaline but not to 5-HT. It is suggested that the agonist action of yohimbine on the ear artery may be mediated via activation of alpha-noradrenoceptors.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7082852

Source DB:  PubMed          Journal:  Blood Vessels        ISSN: 0303-6847


  3 in total

1.  Pharmacological analysis of postjunctional alpha-adrenoceptors mediating contractions to (-)-noradrenaline in the rabbit isolated lateral saphenous vein can be explained by interacting responses to simultaneous activation of alpha 1- and alpha 2-adrenoceptors.

Authors:  C J Daly; J C McGrath; V G Wilson
Journal:  Br J Pharmacol       Date:  1988-10       Impact factor: 8.739

2.  Comparison of the alpha-adrenoceptor antagonist profiles of idazoxan (RX 781094), yohimbine, rauwolscine and corynanthine.

Authors:  J C Doxey; A C Lane; A G Roach; N K Virdee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-02       Impact factor: 3.000

3.  Functional 5-HT receptor subtypes in the isolated canine common carotid artery.

Authors:  S Vhora; S Chiba
Journal:  Heart Vessels       Date:  1994       Impact factor: 2.037

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.